Houston health tech startup launches COVID-19 vaccine management tool

inoculation innovation

Image via luminaremed.com

Houston-based health care software startup Luminare Inc. is arming soldiers in the coronavirus vaccination campaign with technology to help smooth the inoculation process.

Luminare, which launched with the mission of combating sepsis, switched gears after the onset of the coronavirus pandemic to help combat the virus' spread. One of the ways it's doing that is with Innoculate (a mash-up of "innovate" and "inoculate"). The new platform enables organizations like public health departments, fire departments, school systems, and businesses to manage high-volume vaccination initiatives.

Among other benefits, Innoculate automates vaccination sign-ups and scheduling, tracks the number of vaccine batches available, flags previous allergic reactions among vaccine recipients, and helps achieve compliance with federal, state and local health care requirements.

"Usually when you hear news of a new batch of vaccines headed your way, there is dread at the management and distribution overhead. Not anymore," Dr. Sarma Velamuri, CEO of Luminare, says in a release. "Innoculate will help streamline the vaccination process in the fight against COVID-19 and allow for hundreds of thousands of people to get vaccines easily."

One of the first customers of Innoculate is the Corpus Christi-Nueces County Public Health District. Innoculate helped the district vaccinate 9,000 people during the first week of its vaccination effort. Peter Collins, chief information officer of the City of Corpus Christi, says Innoculate allows more vaccinations to be done without adding administrative burdens.

Corpus Christi-Nueces County Public Health District was the first government outfit to use Innoculate. The district also uses Luminare's Quickscreen COVID-19 screening and testing tool.

Dallas County Health and Human Services also is adopting Innoculate. On January 27, Dallas County approved a 12-month contract with Luminare worth up to $601,500.

Other new customers that are lined up for Innoculate include the Abilene-Taylor County Public Health District, Wichita Falls-Wichita County Public Health District, and Brenham-based Blinn College District. Innoculate deals are being finalized with 13 other city and county governments.

Luminare says it wants to "help as many cities and counties in the U.S. that we can." The company asks organizations seeking help with coronavirus vaccination campaigns to email mike.gilbert@luminaremed.com or info@luminaremed.com.

Luminare was founded in 2014 with the goal of preventing sepsis, a life-threatening reaction to a host of infections that triggers about one-third of U.S. hospital deaths. Its sepsis-targeted software is called Sagitta.

After the coronavirus began spreading, Luminare tweaked its sepsis-detection platform, called Quickscreen, to produce a free online self-assessment for people who suspect they've been infected with the virus. The startup was honored for this work as COVID Phoenix in Houston Exponential's inaugural awards program, The Listies. Now, it has added Innoculate to its pandemic-fighting arsenal.

Luminare, based at Texas Medical Center's innovation campus, is a 2018 graduate of the TMCx accelerator. According to Crunchbase, the company has collected more than $1.6 million in funding.

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston humanoid robotics startup taps Amazon veteran to lead manufacturing

new hire

Persona AI, a Houston-based startup that’s developing AI-powered humanoid robots for manufacturers and other businesses, has hired Brian Davis as head of global manufacturing.

Davis previously guided teams at Amazon Robotics and Dell Technologies. During his tenure at Amazon Robotics and Dell, both companies saw major increases in manufacturing volumes within a four-year period. Davis oversaw manufacturing, supply chain, logistics, quality assurance and real estate.

“Davis steps into this role [at Persona AI] as industrial enterprises face an urgent and accelerating challenge: a structural shortage of capacity for welding, fabrication, and heavy maintenance in dynamic environments, precisely the high-value, high-risk tasks where humanoid robots can deliver the greatest impact,” according to a company news release.

Davis comes aboard as Persona AI, founded in 2024, seeks to meet demand generated by deals with HD Hyundai and POSCO Group to make humanoids for shipyards and steel plants, and by a pilot program with the State of Louisiana.

“Now is the perfect time to accelerate our production capabilities as we rapidly close the gap between what’s possible in the lab versus what’s driving real commercial value,” Davis says.

“Building industrial-rated humanoid robots and production-deployable AI is only one piece of the puzzle,” he adds. “Producing humanoids at scale will require systematic supply chain management, stringent quality control, and building the playbook for safe, high-volume manufacturing. That’s what I’m here to build.”

Last year, Persona AI raised more than more than $10 million in pre-seed funding. The company also named a new head of commercial strategy in March.

Houston startup’s brain implant for depression advances to clinical trial

moving forward

Houston-based Motif Neurotech has received FDA approval to move forward with its first clinical trial for its innovative way to fight treatment-resistant depression and other mental health disorders.

The company has developed a brain-computer interface technology based on research from Rice University. The blueberry-sized, wirelessly powered implantable device known as the Digitally-programmable Over-brain Therapeutic (DOT) stimulator delivers electrical stimulation to brain circuits linked to depression. The DOT stimulator sits in the skull above the dura without touching the brain and is considered an alternative to transcranial magnetic stimulation, which requires multiple treatment sessions and can cause headaches.

“The goal for this technology is that it would be the mental health equivalent of a continuous glucose monitor for diabetes,” Jacob Robinson, a Rice University professor of electrical computer engineering and bioengineering and CEO of Motif Neurotech, said in a news release. “What has been really special for me personally on this journey is to be able to work all the way from a concept through the process of research and development funded by the federal government at Rice, and take that into a product that is going to affect people’s lives for the better.”

Eligible adults whose depression has not improved after trying multiple therapies can take part in the study. The clinical trial will be conducted in collaboration with Baylor College of Medicine, Brain Health Consultants (Houston), UT Health Houston, Massachusetts General Brigham, Emory Healthcare, University of Iowa, University of Utah Health and New York University, according to Rice.

Motif also announced that it was one of the first teams selected for ARPA-H’s EVIDENT initiative, which recently awarded up to $139.4 million to spur new, effective therapies for behavioral health. Through the initiative, Motif will collect additional data alongside its clinical trial.

“The idea with this funding is to support a number of teams who have rapid-acting interventions for a mental health condition and to collect additional data to help determine with greater precision whether a treatment is working, how it is working and which patients are benefitting most from which course of treatment,” Robinson added in the release.

Motif Neurotech was spun out of Robinson’s and Professor Kaiyuan Yang’s labs at Rice, along with collaborators and co-founders Dr. Sameer Sheth at Baylor College of Medicine and Dr. Sunil Sheth at the University of Texas Health Science Center at Houston. It was founded through the Rice Biotech Launch Pad. The company closed its Series A round with an oversubscribed $18.75 million last year.

New immersive experience Time Mission clocks into Houston this summer

It's Time

Time for a new immersive experience to come to Houston: Time Mission, a kid-friendly, team-based adventure, is scheduled to land at the Marq-E Entertainment District in summer 2026.

Created by LOL Entertainment, a location-based entertainment company specializing in immersive attractions, Time Mission blends physical and mental challenges in a fast-paced experience, a release says. Players take on real-world tasks like cracking codes, dodging lasers, solving riddles, and exploring hidden tunnels to earn points for their team.

Racing through 25-plus unique portals, teams of two to five players embark on a time-travel journey across the past, present, and future, all while collecting points and battling the clock. The website says the attraction is appropriate for "players age 6 to 106."

“We’ve seen a shift in how people seek entertainment, choosing immersive adventures that foster connection and excitement," says Rob Cooper, CEO of LOL Entertainment, in the release. "We’re excited to introduce [Texas] to an experience where strategy, innovation, and teamwork collide."

There are currently Time Mission locations in Pennsylvania, New York, Rhode Island, Virginia, Illinois, and Belgium. Dallas will be the first Texas location, followed by Houston.

Immersive attractions have been popular in Houston for several years, from Meow Wolf just north of downtown to interactive experiences dedicated to balloons and more.

Time Mission will be located in a 10,000-square-foot space at the Marq-E Entertainment District (7620 Katy Fwy., Ste. 355). The exact opening date will be announced at a later time.

---

This article originally appeared on CultureMap.com.

View All Listings